Sandoz Group (SWX:SDZ) Could Be 38% Below Fair Value On Mixed Half Year Earnings
Sandoz Group (SWX:SDZ) is in focus after its half year 2026 results showed sales of US$5,761 million compared with US$5,232 million a year earlier, while net income and earnings per share were materially lower.
See our latest analysis for Sandoz Group.
The mixed half year earnings update appears to be a key backdrop for Sandoz Group’s recent price strength, with the share price at CHF72.78 and a 1 day share price return of 5.20%. That sits within a strong run, with momentum building as the 7 day share price return is 10.68%, the 30 day share price return is 7.38%, the 90 day share price return is 8.95%, the year to date share price return is 27.19% and the 1 year total shareholder return is 55.77%.
If earnings swings and regulatory news have you thinking more broadly about opportunities, it could be a good moment to scan other healthcare leaders using our screener for 130 healthcare AI stocks
Sandoz Group’s sharp move after earnings sits between two stories. One points to a stronger business behind higher sales. The other hints at sentiment reacting to compressed profits. The valuation now has to bridge that gap.
Most Popular Narrative: 2.9% Overvalued
Sandoz Group closed at CHF72.78, a touch above the narrative fair value of CHF70.74, which frames how analysts view its long term earnings potential under a 3.94% discount rate.
Regulatory streamlining and investments in advanced in-house manufacturing (notably Slovenia expansion and Just-Evotec acquisition) are expected to lower production costs and speed up time-to-market for new biosimilars, driving margin expansion and higher net earnings.
Want to see why this margin story still supports a premium price tag for Sandoz Group? The narrative leans on rising earnings power, richer product mix, and a future profit multiple that assumes investor confidence holds up.
Result: Fair Value of CHF70.74 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Sandoz Group still faces pressure from pricing in generics and biosimilars, and any setbacks at its new Slovenia biosimilar hub could quickly test this valuation narrative.
Find out about the key risks to this Sandoz Group narrative.
Another View on Sandoz Group’s Valuation
The analyst narrative sees Sandoz Group as 2.9% overvalued at CHF72.78 versus a CHF70.74 fair value. Our DCF model points in the opposite direction, with a fair value estimate of CHF117.98. That is a 38.3% gap. Which story do you think fits your own assumptions?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sandoz Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 263 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this mix of optimism and caution around Sandoz Group leaves you undecided, consider reviewing the numbers yourself and pressure testing the thesis using the 3 key rewards.
Looking for more investment ideas beyond Sandoz Group?
If Sandoz Group has sharpened your interest in healthcare and valuation stories, do not stop here. Broader idea hunting can give you useful context and fresh angles.
- Spot potential mispricings early by scanning companies that look attractively valued on quality and fundamentals using the 263 high quality undervalued stocks.
- Focus on income potential and consistency by reviewing companies that appear in the 440 dividend fortresses.
- Prioritise resilience by filtering for companies that pass tight risk checks through the 298 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com